FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| Check this box if no longer subject to |
|--|
| Section 16. Form 4 or Form 5 |
| obligations may continue. See |
| Instruction 1(b). |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | | | | | _ | | | | | | | | | | | | | | | |
|--|--|------------|--|----------------------------|-------|--|---|-----|--|-----|--|--|--|---|--|---|--|---|--|--|
| 1. Name and Address of Reporting Person* COELHO PHILIP H | | | | | | | 2. Issuer Name and Ticker or Trading Symbol CATALYST PHARMACEUTICALS, INC. | | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner | | | | | |
| | | | | | | | [CPRX] | | | | | | | | Officer (give title | | | pecify | | |
| (Last) (First) (Middle) | | | | | | | | | | | | | | below) below) | | | pecity | | | |
| 355 ALHAMBRA CIRCLE, SUITE 1250 | | | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 12/19/2018 | | | | | | | | | | | | | |
| (Street) CORAL GABLES | • | | | | 4. II | 4. If Amendment, Date of Original Filed (Month/Day/Year) | | | | | | | | Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person | | | | | | |
| GIIDLE | | | | | - | | | | | | | | | Form filed by More than One Reporting Person | | | | | | |
| (City) | ty) (State) (Zip) | | | | | | | | | | | | | | | | | | | |
| Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | | | | | |
| 1. Title of Security (Instr. 3) 2. Transar Date (Month/Date | | | | | | ear) | 2A. Deemed Execution Date, if any (Month/Day/Year) | | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5) | | | Benefici | ally Following | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | | 7. Nature of Indirect Beneficial Ownership | | |
| | | | | | | | | | Code V | , , | Amount | (A) o (D) | Price | Transact | nsaction(s) str. 3 and 4) | | | (Instr. 4) | | |
| Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) | tive Conversion Date Execution or Exercise (Month/Day/Year) if any | | | Date, Transact Code (In | | | | | 6. Date Exercisable Expiration Date (Month/Day/Year) | | | nd 7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Beneficial Ownership (Instr. 4) | | |
| | | | | | Code | v | (A) | (D) | Date Exercisable | | piration te | Title | Amount or Number of Shares | | | | | | | |
| Options to purchase common stock | \$2.24 | 12/19/2018 | | | A | | 25,000 | | 12/19/2018 | 12/ | 19/2025 | Common Stock | 25,000 | \$0 | 265,00 | 00 | D | | | |
| Options to purchase common | \$2.24 | 12/19/2018 | | | A | | 25,000 | | 12/19/2019 | 12/ | 19/2025 | Common Stock | 25,000 | \$0 | 290,00 | 00 | D | | | |

Explanation of Responses:

/s/ Philip H. Coelho

12/20/2018

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).